Germany's Federal Court of Justice - wingrim / Shutterstock.com
A decision by Germany’s Federal Court of Justice has developed the concept of the ‘doctrine of equivalents’, possibly benefiting pharma patent owners, say Bernd Allekotte and Markus Grammel of Grünecker.
The German Federal Court of Justice (FCJ) considered the infringement of a Swiss-type medical use claim under the doctrine of equivalents for the first time in the June decision of X ZR 29/15 (Pemetrexed).
The FCJ used this opportunity to clarify its previous decisions of Okklusionsvorrichtung and Diglycidverbindung, which have been widely perceived as significantly reducing the scope of protection of a patent under the doctrine of equivalents in Germany. Some litigators even have considered these decisions to be the final nail in the coffin of the doctrine of equivalents for Germany.
On the one hand, the present Pemetrexed decision limits the applicability of the restrictive Okklusionsvorrichtung and Diglycidverbindung decisions; on the other hand, however, in contrast to current practice, the FCJ seems to be willing to take into account a patent’s file-wrapper (electronic file) in the future.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
patent, Bernd Allekotte, Markus Grammel, Grünecker, patent, Germany, German Federal Court of Justice, medical